

## Functional Requirement for Threonine in the P<sub>2</sub> Position of a Cyclic Peptide Mimetic of a Bowman-Birk Proteinase Inhibitor

Jeffrey D. McBride, Arnd B.E. Brauer, Marco Nieveo  
and Robin J. Leatherbarrow

*Department of Chemistry, Imperial College of Science, Technology, and Medicine,  
South Kensington, London SW7 2AY, UK*

We have used the anti-tryptic loop region of the Bowman-Birk proteinase inhibitor; MAI/D4 to create a template assisted combinatorial peptide library to screen for peptides displaying re-directed activity towards chymotrypsin [1]. The inhibitory sequences discovered were found to have both high activity and display a consensus binding motif. One surprising feature was that all active sequences were found to have exclusively threonine in the P<sub>2</sub> position. The reason for this specificity has been probed by maintaining the binding motif but systematically varying the P<sub>2</sub> locus to create a further 24 variants. It is found that the requirements for inhibitory activity at this locus are finely tuned. The results are consistent with a dual requirement for hydrophobic recognition with the enzyme pocket and maintenance of an inhibitory conformation, presumably formed by a hydrogen bond within the peptide loop.

### Introduction

Inhibition by serine proteinase inhibitor proteins is often mediated by an exposed loop that is fixed in a characteristic "canonical" conformation, thought to be similar to that of a productively bound substrate [2,3]. The sequence of the loop determines the specificity of the inhibition, which mirrors the specificity of proteinases for their substrates.

The Bowman-Birk family of serine proteinase inhibitors (BBI's) are small proteins (6-9 kD) with a symmetrical structure of two tricyclic domains each containing an independent binding loop [4]. The proteinase binding loop is typically contained within a nonapeptide region joined *via* a disulfide between flanking cysteines. We have used an eleven amino acid monocyclic peptide [5] derived from the anti-tryptic loop domain of BBI as a template for construction of a "one bead, one peptide" library [6] in which three locations considered important for proteinase recognition were varied (P<sub>1</sub>, P<sub>2</sub>, and P<sub>2</sub>') [1]. When this library was screened for re-directed activity against chymotrypsin, active sequences were found to contain exclusively threonine at the P<sub>2</sub> site; the P<sub>1</sub> site had phenylalanine and tyrosine; and leucine, isoleucine and norleucine

were found at P<sub>2</sub>' [1]. Although the preference for aromatic residues at P<sub>1</sub> is consistent with the substrate preference of chymotrypsin, the sequences obtained at the other locations were less predictable, and it was particularly striking that exclusively threonine was found at the P<sub>2</sub> location.

In order to evaluate further what features of the P<sub>2</sub> locus are necessary to the properties of the peptide mimetic, we have undertaken a systematic kinetic analysis of 25 variations of the consensus chymotrypsin binding motif: SCXFSIPPQCY (P<sub>2</sub> position shown in bold).

## Materials and Methods

### *Peptide synthesis and purification.*

Peptides for kinetic analysis were synthesized by standard solid phase techniques as described previously [1]. All peptides were characterized by FAB-MS and were >85% by analytical reverse phase HPLC.

### *Inhibition kinetics.*

The inhibition kinetics were determined by competitive binding studies using the chromogenic substrate succinyl-Ala-Ala-Pro-Phe-*p*-nitroanilide as previously [1].

## RESULTS

### *Effect of P<sub>2</sub> variation on K<sub>i</sub>*

Using the consensus sequence (SCTFSIPPQCY; P<sub>2</sub> residue in bold) found for re-directed activity of the anti-tryptic loop towards chymotrypsin, a range of P<sub>2</sub> variants was synthesised. The individual K<sub>i</sub> values are given in Table 1.

**Table 1.** *Equilibrium dissociation constants for P<sub>2</sub> variants of the chymotrypsin re-directed anti-tryptic loop of MAI-D4. N.I., no detectable inhibition.*

| P <sub>2</sub> residue | K <sub>i</sub> (μM) | P <sub>2</sub> residue | K <sub>i</sub> (μM) |
|------------------------|---------------------|------------------------|---------------------|
| Thr                    | 0.019               | Pro                    | 5.2                 |
| Abu                    | 0.13                | Gln                    | 7.1                 |
| Nva                    | 0.28                | Phe                    | 8.7                 |
| Ser                    | 0.4                 | Trp                    | 9                   |
| Ala                    | 0.57                | Ile                    | 13.4                |
| Val                    | 1.3                 | Asn                    | 17                  |
| His                    | 1.4                 | Tyr                    | 17.1                |
| Arg                    | 1.8                 | Glu                    | 84                  |
| Met                    | 2.2                 | Asp                    | 98                  |
| Leu                    | 2.4                 | <i>allo</i> -Thr       | >100                |
| Hse                    | 2.6                 | <i>t</i> -butylglycine | >100                |
| Lys                    | 2.8                 | D-Thr                  | N.I.                |
| Gly                    | 4.4                 |                        |                     |

## Discussion

### *P<sub>2</sub> Specificity found in this study*

The results confirm a significant influence of the P<sub>2</sub> locus of the peptide. In addition to those residues present in our earlier library, the following amino acids were also examined: Abu, Nva, Hse, *allo*-Thr, D-Thr and *t*-butylglycine. The results confirm that of those variants tested, Thr is optimal. This explains why our earlier library studies [1] returned exclusively Thr at this location.

The requirements for inhibitory activity at this locus are found to be finely tuned. Inversion of asymmetric  $\beta$ -carbon from R to S (*allo*-Thr) results in a very poor inhibitor, as does the replacement of L-Thr with D-Thr. Loss of either the  $\beta$ -hydroxyl or methyl functions of the threonine results in a significant loss of activity. Whilst the loss of the hydroxyl gives a 6.8 fold reduction in activity (Abu), the loss of the methyl (Ser) gives a 21 fold reduction in activity. In the absence of the hydroxyl function, the homologous series Ala, Abu and Nva further demonstrate the requirement for methyl group attached to the  $\beta$ -carbon. When the aliphatic sidechain is reduced to Ala there is an approximate 4 fold loss in activity compared to Abu and increase of the alkyl length to Nva results in a more modest 2 fold loss in activity. Branching of the aliphatic sidechain results in further loss of activity. Hence, valine has a 10 fold higher  $K_i$  than Abu. Similarly, in contrast to Ala, *t*-butylglycine is of extremely low activity and branching at the  $\gamma$ -carbon gives an 8.5 fold higher  $K_i$  when comparing Leu and Nva. In a similar fashion, the requirement for a  $\beta$ -hydroxyl is demonstrated by comparing Ser and Hse with a  $\gamma$ -hydroxyl resulting in a  $K_i$  6.5 fold higher than the  $\beta$  equivalent. The crystal structure of a BBI-trypsin complex shows a hydrogen bond between P<sub>2</sub> Thr and P<sub>1</sub>' Ser, and a hydrophobic contact between the  $\gamma$ -methyl and His-57 [7]. These interactions would explain why both hydroxyl and methyl groups of the threonine residue are important.

Large aliphatic or aromatic side chains result in relatively poor inhibitors, suggesting that they are not well accommodated in the S<sub>2</sub> pocket. Particularly noteworthy is the extremely poor inhibition when a negatively-charged residue is present at P<sub>2</sub> (Asp, Glu). It is possible that these side chains result in an unfavourable electrostatic interactions with Asp-102 of the catalytic triad.

### *Implications for Library Screening*

Our original screening procedure produced exclusively Thr at P<sub>2</sub> [1]. The present results show that the next best sequence that was present at this locus, Ser, had a  $K_i$  value that was higher by a factor of 20. This indicates that the selection procedure depends of the  $K_i$  value, and that a twenty-fold difference is sufficient to give complete selectivity.

## Acknowledgments

This work was supported by the BBSRC and Glaxo Wellcome Research.

**References**

- 1 McBride, J.D., Freeman, N., Domingo, G.J. and Leatherbarrow, R.J. (1996) *J. Mol. Biol.* **259** 819-827
- 2 Laskowski, M., Jr. & Kato, I. (1980) *Annu. Rev. Biochem.* **49**, 593-626.
- 3 Bode, W. & Huber, R. (1992) *Eur. J. Biochem.* **204**, 433-451.
- 4 Chen, P., Rose, J., Loves, R., Wei, C.H., & Wang, B. (1992) *J. Biol. Chem.* **267**, 1990-1994.; Werner, M.H. & Wemmer, D.E. (1992) *Biochemistry* **31**, 999-1010.; Lin, G., Bode, W., Huber, R., Chi, C. & Engh, R.A. (1993) *Eur. J. Biochem.* **212**, 549-555.
- 5 Maeder, D.L., Sunde, M. and Botes, D.P. (1992) *Int. J. Peptide Protein Res.* **40**, 97-102.
- 6 Lam, K.S., Salmon, S.E., Hersh, E.M., Hruby, V.J., Kazmierski, W.M., & Knapp, J.J. (1991) *Nature (London)* **354**, 82-84.; Furka, A., Sebestyen, F., Asgedom, M. & Dibo, G. (1991) *Int. J. Pept. Protein Res.* **37**, 487-493.
- 7 Lin, G., Bode, W., Huber, R., Chi, C & Engh, R.A. (1993) *Eur. J. Biochem.* **212**, 549-555.